Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

875 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A; Gynecologic Cancer Program of Dana Farber-Harvard Cancer Center. Matulonis UA, et al. Among authors: campos s. Gynecol Oncol. 2006 Oct;103(1):160-4. doi: 10.1016/j.ygyno.2006.02.017. Epub 2006 Mar 29. Gynecol Oncol. 2006. PMID: 16566993 Clinical Trial.
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Vasey PA, et al. Among authors: campos s. J Clin Oncol. 2002 Mar 15;20(6):1562-9. doi: 10.1200/JCO.2002.20.6.1562. J Clin Oncol. 2002. PMID: 11896105 Clinical Trial.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Burstein HJ, et al. J Clin Oncol. 2003 Aug 1;21(15):2889-95. doi: 10.1200/JCO.2003.02.018. J Clin Oncol. 2003. PMID: 12885806 Clinical Trial.
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV; Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care; Dana Farber-Harvard Cancer Care. Matulonis U, et al. Among authors: campos s. Gynecol Oncol. 2003 Nov;91(2):293-8. doi: 10.1016/s0090-8258(03)00496-7. Gynecol Oncol. 2003. PMID: 14599858 Clinical Trial.
Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. del Carmen MG, et al. Among authors: campos s. Gynecol Oncol. 2003 Dec;91(3):596-602. doi: 10.1016/j.ygyno.2003.08.021. Gynecol Oncol. 2003. PMID: 14675683 Clinical Trial.
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
Penson RT, Seiden MV, Goodman A, Fuller AF Jr, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM; Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare. Penson RT, et al. Among authors: campos sm. Gynecol Oncol. 2004 Jun;93(3):702-7. doi: 10.1016/j.ygyno.2004.02.028. Gynecol Oncol. 2004. PMID: 15196868 Clinical Trial.
875 results